In a phase II trial, an oral HDAC inhibitor, CI994 (tacedinaline), combined with gemcitabine did not improve overall survival in pancreatic cancer as compared to gemcitabine alone [65]. The gene discussed is HDAC9; the disease is familial pancreatic carcinoma.